login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
ALTIMMUNE INC (ALT) Stock News
USA
- NASDAQ:ALT -
US02155H2004
-
Common Stock
4.17
USD
+0.11 (+2.71%)
Last: 11/14/2025, 8:00:00 PM
4.17
USD
0 (0%)
After Hours:
11/14/2025, 8:00:00 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
ALT Latest News, Press Relases and Analysis
All
Press Releases
5 days ago - By: Altimmune, Inc
Altimmune Announces Publication of IMPACT Phase 2b Trial Data in The Lancet and Concurrent Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2025
9 days ago - By: Altimmune, Inc
Altimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from IMPACT Phase 2b Trial of Pemvidutide in MASH in Late-breaking Poster at AASLD The Liver Meeting® 2025
10 days ago - By: Benzinga
- Mentions:
STVN
PODD
AMRK
SOLV
...
Earnings Scheduled For November 6, 2025
11 days ago - By: Altimmune, Inc
Altimmune to Participate in Two Upcoming Investor Conferences
13 days ago - By: Altimmune, Inc
Altimmune Announces Early Completion of Enrollment in RECLAIM Phase 2 Trial Evaluating Pemvidutide in Alcohol Use Disorder
a month ago - By: Benzinga
Altimmune Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
17 days ago - By: Altimmune, Inc
Altimmune to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025
a month ago - By: Altimmune, Inc
Altimmune to Present Phase 2b IMPACT Data on Pemvidutide in MASH in Late-Breaking Oral Podium Presentation and Late-Breaking Poster at AASLD The Liver Meeting® 2025
a month ago - By: Grabar Law Office
- Mentions:
FIVE
FLYW
HTZ
Important Notice to Long-Term Shareholders of Altimmune, Inc. (NASDAQ: ALT); Five Below, Inc. (NASDAQ: FIVE); Flywire Corporation (NASDAQ: FLYW); and Hertz Global Holdings, Inc. (NASDAQ: HTZ): Grabar Law Office is Investigating Claims on Your Behalf
a month ago - By: Bragar Eagel & Squire
ALTIMMUNE ALERT: Bragar Eagel & Squire, P.C. is Investigating Altimmune, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
a month ago - By: Faruqi & Faruqi, LLP
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune
a month ago - By: Bragar Eagel & Squire
ALTIMMUNE FINAL DEADLINE REMINDER: Bragar Eagel & Squire, P.C. Urges Investors to Contact the Firm Regarding the October 6th Deadline
a month ago - By: Levi & Korsinsky, LLP
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Altimmune, Inc.(ALT) Shareholders
a month ago - By: Faruqi & Faruqi LLP
ALT INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune
a month ago - By: Bragar Eagel & Squire
ALTIMMUNE CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. Reminds Investors of October 6th Deadline and Urges Investors to Contact the Firm
a month ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALT
a month ago - By: Faruqi & Faruqi, LLP
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune
2 months ago - By: THE ROSEN LAW FIRM, P. A.
ALT Deadline: ALT Investors with Losses in Excess of $50K Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit
2 months ago - By: Berger Montague
Altimmune, Inc. (NASDAQ: ALT) Deadline Approaching: Berger Montague Advises Investors of Deadline in Securities Fraud Lawsuit
2 months ago - By: The Rosen Law Firm PA
ALT DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 6 Deadline in Securities Class Action - ALT
2 months ago - By: DJS Law Group
Altimmune, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – ALT
2 months ago - By: Faruqi & Faruqi LLP
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune
2 months ago - By: Berger Montague
DEADLINE APPROACHING: Berger Montague Advises Altimmune, Inc. (NASDAQ: ALT) Investors to Inquire About a Securities Fraud Class Action by October 6, 2025
2 months ago - By: Bragar Eagel & Squire
ALTIMMUNE (ALT) DEADLINE ALERT: Bragar Eagel & Squire, P.C. Urges Investors to Contact the Firm Before the October 6th Deadline in the Altimmune Class Action Lawsuit
2 months ago - By: THE ROSEN LAW FIRM, P. A.
ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit
2 months ago - By: The Gross Law Firm
Shareholders that lost money on Altimmune, Inc.(ALT) should contact The Gross Law Firm about pending Class Action - ALT
2 months ago - By: Altimmune, Inc
Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide
2 months ago - By: The Rosen Law Firm PA
ALT DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important October 6 Deadline in Securities Class Action - ALT
Please enable JavaScript to continue using this application.